Bryan Stuart's Insider Trades & SAST Disclosures
Bryan Stuart's most recent trade in Fulcrum Therapeutics Inc was a trade of 340,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 19, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Bryan Stuart.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics Inc | Bryan Stuart | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 340,000 | 340,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Bryan Stuart | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 10 Aug 2021 | 32,000 | 32,000 (0%) | 0% | 7.8 | 250,880 | Common Stock |
| Fulcrum Therapeutics Inc | Bryan Stuart | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 32,000 | 271,571 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Bryan Stuart | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 10 Aug 2021 | 32,000 | 0 (0%) | 0% | 17.5 | 560,000 | Common Stock |
| Fulcrum Therapeutics Inc | Bryan Stuart | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 28,000 | 243,571 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Bryan Stuart | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 23.75 per share. | 10 Aug 2021 | 28,000 | 0 (0%) | 0% | 23.8 | 665,000 | Common Stock |
| Fulcrum Therapeutics Inc | Bryan Stuart | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 10 Aug 2021 | 28,000 | 28,000 (0%) | 0% | 7.8 | 219,520 | Common Stock |
| Fulcrum Therapeutics Inc | Bryan Stuart | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 350,000 | 350,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Bryan Stuart | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 134,376 | 134,376 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges